טוען...
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
Direct oral anticoagulants (DOACs) were developed to compensate for the demerits of warfarin. In Japan, three factor Xa inhibitors are used for the treatment of venous thromboembolism (VTE): edoxaban, rivaroxaban, and apixaban. Despite problems, such as the inability to monitor their effect and the...
שמור ב:
| הוצא לאור ב: | J Atheroscler Thromb |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Japan Atherosclerosis Society
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5453680/ https://ncbi.nlm.nih.gov/pubmed/28392512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5551/jat.RV17005 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|